Aicone Biochip

World’s first fully quantitative, COVID-19 Antibody Test – Full titres of all  Ig classes/subclasses, IgG, IgA, IgM; IgG1-4


Aicone Biochip is a multi-antigen, multi-domain, fully quantitative serology COVID-19 test.

Aicone Biochip™ enables the determination of the target epitopes, titres and Ig class/sub-class (IgG, IgA, IgM; IgG1-4) of antibodies produced across all stages of COVID-19 infection, from initial exposure, disease development, post-recovery or post-vaccination. These results will provide critical insights on whether individuals have high titres of potentially neutralising antibodies against SARS-CoV-2 that may protect against reinfection or whether booster vaccinations are required.

Until recently there was no COVID-19 antibody test available to provide a quantitative result. That has changed. The Aicone Biochip test is based on the differential ratio between Ig class/sub-classes across the 4 SARS-CoV-2 antigens to give an estimation of an individual’s stage of infection and immunity. This is unmatched by any other test.

Aicone Biochip is a lab-based biochip test that utilises protein folding technology ensuring that viral antigens are correctly folded, preserving all conformational and linear antibody binding sites. Aicone-Protein Array which is utilized by major pharma and research entities to develop vaccines and therapeutics, ensures that the test identifies more true positives and less false negative.

Cross-reactivity between immunogenic regions of SARS-CoV-2 and other coronaviruses may lead to an overestimation of sero-prevalence in a given population. Aicone Biochip is designed to reduce cross-reactivity by targeting multiple SARS-CoV-2 specific domains, resulting in fewer false positives, and a more accurate determination of sero-prevalence.

The Aicone Biochip product range is biochip-based. They all incorporate multiple additional viral antigens. They are designed for research and clinical vaccination trials. See the Product Description for full details.

Content can be customised based on individualised requirements for vaccine clinical trials or sero-prevalence research studies.


Aicone Biochip can be utilised for vaccine clinical trials or sero-prevalence research studies. 

COV2 | EN | Aicone Biochip

Population antibody profiling for sero-prevalence research

The target epitope of antibodies produced following infection exhibit a significant level of diversity across a population. Aicone Biochip provides a more accurate determination of sero-prevalence by targeting over 10 different domains of SARS-CoV-2 proteins.


Determine the protective quality and quantity of antibodies produced

Some individuals produce antibodies that target locations which are neutralising (protective), whereas others produce non-neutralising antibodies. Aicone Biochip can be used to identify individuals who have high titres of potentially neutralising antibodies against SARS-CoV-2.


Enable quantitative assessment of antigen-specific response by individuals in vaccine trials

As shown below, data from Aicone Biochip tests enable 3 major conclusions to be inferred:
1. There is a wide variation in antibody titres across SARS-CoV-2 infected individuals
2. There is a high degree of variation in patient-specific antibody responses to the different domains of SARS-CoV-2 proteins
3. Wider coverage of target epitopes leads to increased sensitivity and specificity


Product Description

39508H and 39508V have 24 arrays per slide, 39508R has 8 arrays per slide.

Product Specification

Biochip Layout

Control Probes

  • Positive control
    1. Cy3-BSA
    2. Cy5-BSA
    3. IgA (positive control for total immunoglobulins detection)
    4. IgG (positive control for IgG and total immunoglobulins detection)
    5. IgM (positive control for IgM and total immunoglobulins detection)
  • Negative control
    1. IgA (negative control for IgG and IgM detection)
    2. IgG (negative control for IgM detection)
    3. IgM (negative control for IgG detection)
    4. Negative control probe for total immunoglobulins detection


Technical Details of Main Antigens

Western blot analyses showing successful expression of CoV and Influenza proteins using Aicone-Protein Array:


Aicone-Protein Array facilitates measures of antibodies at unrivalled sensitivity and specificity, making it a vastly superior to other antibody platforms. Because all the proteins on Aicone-Protein Array protein arrays are correctly folded, conformational as well as non-conformational epitopes are available for binding to antibodies. Since 90% of antibody binding sites are conformational in nature, if the protein is not full length or not correctly folded, other protein arrays actually lead to the loss of binding to these conformational epitopes. Using Aicone-Protein Array protein arrays ensures the binding of antibodies to not just linear, non-conformational epitopes but also to discontinuous conformational epitopes.

The main advantage of the Aicone-Protein Array based array is that the immobilised protein is folded in its native conformation, due to the BCCP fusion and the absence of physical protein purification which may affect epitope exposure for recognition.

*90% of antibodies bind to conformational epitopes, references:

  1. Barlow, D. J., Edwards, M. S., & Thornton, J. M. (1986). Continuous and discontinuous protein antigenic determinants. Nature, 322(6081), 747–748;
  2. Van Regenmortel, M. H. V. (2006, May). Immunoinformatics may lead to a reappraisal of the nature of B cell epitopes and of the feasibility of synthetic peptide vaccines. Journal of Molecular Recognition, 19(3), 183–187.


Interferons – Antinuclear antibodies – Tumour Necrosis Factor

All the proteins including controls are fabricated on the same array in triplicate. Below is the list of proteins on Aicone COVID+ V2 array :

  1. Interferons (IFN) (-α, – γ, -ω) – 4 antigens
  2. Antinuclear antibodies (ANA) related antigens – 4 antigens
  3. Tumour Necrosis Factor (TNF) α – 1 antigen
  4. SARS-CoV-2 Nucleocapsid antigen – 6 domains
  5. SARS-CoV-2 Spike antigen – 3 domains including full length
  6. Controls (Cy3-BSA, IgG x 2 dilutions, IgA x 2 dilutions, IgM x 2 dilutions, BCCP, polyspecific identifier x 2) – 10 components

IFNs and TNF were added to the chip to act as components to predict disease course and outcome through measurement of direct antibody binding. In addition to that, the elevation of TNF-α and IL-6 in serum from COVID-19 patients have been shown as a strong predictors of disease severity and survival. The information obtained from the chip on these cytokines will facilitate potential mitigation strategy in managing COVID-19.

Tumor Necrosis Factor TNF-α is an inflammatory cytokine produced by the immune system cells (macrophages) during acute inflammation. The main role of this cytokine involves signaling for ‘apoptosis’ meaning the cell needs to be destroyed.

Antinuclear Antibodies are autoantibodies that bind to contents of the cell nucleus. In normal individuals, the immune system produces antibodies to foreign antigens but not to human autoantigens.

IFNγ, or type II interferon, is a cytokine that is critical for innate and adaptive immunity against viral, some bacterial and protozoal infections. IFNγ is an important activator of macrophages and inducer of Class II major histocompatibility complex (MHC) molecule expression. Aberrant IFNγ expression is associated with a number of autoinflammatory and autoimmunediseases.

IFNs and TNF were added to the chip to act as components to predict disease course and outcome in COVID-19 infected persons through measurement of direct antibody binding. The Biochip is able to quantify the Immune Response. All the proteins including controls are fabricated on the same array in triplicate.  


AICONE’s COVID-19 antigens are correctly folded, preserving all conformational antibody binding sites.

AICONE BIOCHIP Leverages AICONE-PROTEIN ARRAY World’s Only Correctly Folded Protein Technology

  • Since most antibodies are thought to recognise discontinuous epitopes on their target proteins, it’s critical that antigens used in serological assays or presented to B-cells for antibody-based vaccine development are in a natively-folded form.
  • The use of Aicone-Protein Array technology for the production of the SARS-CoV-2 antigens will ensure these antigens are correctly folded, preserving all conformational antibody binding sites.

Surface Chemistry of Aicone-Protein Array 

  • BCCP-tagged, biotinylated Aicone-Protein Array proteins are immobilised onto a customised streptavidin-coated hydrogel surface.
  • Aicone-Protein Array proteins retain their folded structure and function as if they are present in an aqueous environment.
  • Proteins behave as if they are in free solution.


Exceptional Consistency

Protein arrays made with the Aicone-Protein Array technology exhibit exceptional consistency as measured by the coefficient of variation percentage (CV%).

The graph shows the CV% of intra-protein replicates run on a Aicone-Protein Array based protein array (Immunome) compared to a non-Aicone-Protein Array protein array (PX). The mean CV% for Immunome was 7.2% whereas the CV% for protein array PX was 37%.

Very high Specificity

The correct folding of proteins on Aicone-Protein Array protein arrays ensures that both continuous and discontinuous epitopes are preserved, hence all antibody binding sites are available. This leads to Aicone-Protein Array arrays having very high specificity, and by extension, a high signal-to-noise ratio.

Highly Reproducible

Aicone-Protein Array based protein arrays use multiple positive and negative controls to measure reproducibility within, and across, studies and batches.

The graph shows an almost perfect Pearson correlation of above 0.97 when comparing auto-antibody levels across 6,524 protein data points in two different batches.

Picomolar Sensitivity

Auto-antibodies on Aicone-Protein Array based protein arrays can be detected at very high sensitivity, only 1 – 10 µl of serum is required. The detection limit is in the 10 pg/ml range, with a linear dynamic range of at least 5 orders of magnitude.